Close Menu

NEW YORK – Thermo Fisher Scientific said on Tuesday that the US Food and Drug Administration has granted premarket approval for its Oncomine Dx Target Test as a companion diagnostic for pralsetinib (Gavreto), a targeted drug developed by Blueprint Medicines, to identify RET fusions in metastatic non-small cell lung cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
26

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.